MedTrace Logo

Cardiac Sarcoidosis and FDG-PET

NCT00958087 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2012-09-27

No results posted yet for this study

Summary

Sarcoidosis is a multi-systemic inflammatory disorder of unknown cause characterized by the formation of non-caseating granulomas in involved organs. Its cardiac involvement may be potentially fatal. Although endomyocardial biopsy is required for definitive diagnosis of cardiac sarcoidosis, it is invasive and lacks sensitivity. The specific diagnostic tool for cardiac sarcoidosis is far from satisfactory. Recent studies have revealed that FDG-PET with under fasting conditions is a useful method for identification of cardiac sarcoidosis patients. However, to our knowledge, no investigations have been published with regard to FDG quantification for the diagnosis and management of cardiac sarcoidosis by PET.

Conditions

  • Sarcoidosis
  • Dilated Cardiomyopathy

Sponsors & Collaborators

  • Kurume University

    lead OTHER

Principal Investigators

  • Nobuhiro Tahara, MD, PhD · Kurume University

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2010-03-31
Completion
2010-07-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958087 on ClinicalTrials.gov